Massive opportunity in AI-enhanced heart healthcare.
| Since heart disease is the world’s #1 leading cause of death, it’s no surprise when an AI company working to solve it gets a “Strong Buy” rating from analysts—and a 270% 1-year price target.
For decades, millions with heart disease have gone undiagnosed because effective heart diagnostics are expensive and require cardiologists.
But HeartSciences (Nasdaq: HSCS) is helping bridge that gap. Their AI-ECG, developed with Mount Sinai, brings specialist-grade insights to routine frontline exams so issues will be caught faster and more affordably by frontline doctors.
And they’re hitting several major milestones as we speak:
First commercial customer for their software platform, a cardiology center providing services to the UK’s NHS, one of the largest healthcare networks in the world
FDA Breakthrough Device Designation, providing priority review and a faster path to market
New foundational U.S. patent issued, bringing the total to 44 granted patents and further protecting their AI-ECG technology from competitors
FDA submission for their device expected for summer 2025
While HeartSciences is already public, they’re giving investors an opportunity not available on the public exchange: $3.50 units that include 1 share of convertible preferred stock + 1 warrant.
Together, it all amounts to 500% upside based on analyst projections.
Learn more and invest in HeartSciences today. |
|
This is a paid advertisement for HeartSciences Regulation A+ offering. Please read the offering circular at https://invest.heartsciences.com/
|
|
|
|
|
| This content is sponsored by Eunice.io Enjoyed the content? Eunice is a financial newsletter that provides in-depth market analysis on stocks of interest to individual investors. If you care at all about the market, Eunice is the newsletter for you. Subscribe here You can also join our Telegram channel for real-time updates about what stocks are moving: Or join our Whatsapp group for trade alerts |
|
|
|
|
|
|
In order to unsubscribe from this mailing list, please click
here 